nivolumab,relatlimab,ipilimumab
bms
['nivo']
to be clear, today's #asco2023 results according to subsequent therapy are not satisfactory to me. looks like too few patients got ipi-nivo in almost half of them (7/16), we don't know the response
6/7 
Medicine, Oncology (sarcoma, H&N, CUP), Research = EBM, Epi, Policy #metaresearch @Hopitaux_unige (Geneva, CH), @vkprasadlab (UCSF). No COI. Views mine.